Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection

Lancet

Volumn 351, Issue 9105, 1998, Pages 786-792

  Halsey, Neal A ^a,d   Coberly, Jacqueline S ^a   Desormeaux, Julio ^b   Losikoff, Phyllis ^a   Atkinson, Joan ^a   Moulton, Lawrence H ^a   Contave, Mireil ^b   Johnson, Michael ^a   Davis, Homer ^b   Geiter, Lawrence ^c   Johnson, Erica ^a   Huebner, Robin ^c   Boulos, Reginald ^b   Chaisson, Richard E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Centres pour le Devmt et la S   (Haïti)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVELOPING COUNTRY; DIARRHEA; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; SKIN TEST; STOMACH PAIN; SURVIVAL; THORAX RADIOGRAPHY; TUBERCULOSIS;

EID: 0032515836     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)06532-X     Document Type: Article

References (31)

1. 1 Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320: 545-50.
2. 2 Allen S, Battungwanayo J, Kerlikawske K, et al. Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. Am Rev Respir Dis 1992; 146: 1439-44.
3. 3 Markowitz N, Hansen NI, Hopewell PC, et al. Incidence of tuberculosis in the United States among HIV-Infected persons. Ann Intern Med 1997; 126: 123-32.
4. 4 Guelar A, Gatell JM, Verdejo J, et al. A prospective study of the risk of tuberculosis among HIV-1 infected patients. AIDS 1993; 7: 1345-49.
5. 5 Ferebee S. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res 1970; 17: 28-106.
6. 6 Comstock G, Ferebee S. How much isoniazid is needed for prophylaxis? Am Rev Respir Dis 1970; 101: 780-82.
7. 7 International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60: 555-64.
8. 8 Comstock GW, Wollpert SF, Baum C. Isoniazid prophylaxis among Alaskan Eskimos: a progress report. Am Rev Respir Dis 1974; 110: 195-97.
9. 9 Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342: 268-72.
10. 10 Graham NM, Galai N, Nelson KE, et al. Effect of isoniazid chemopropphylaxis on HIV-related mycobacterial disease. Arch Intern Med 1996; 156: 889-94.
11. 11 World Health Organization. Tuberculosis preventive therapy in HIV-infected individuals. Wkly Epidemiol Rec 1993; 68: 361-64.
12. 12 DeCock KM, Soro B, Coulibaly IM, Lucas SM. Tuberculosis and HIV infection in Sub-Saharan Africa. JAMA 1992; 268: 1581-87.
13. 13 Snider DE Jr, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992; 145: 494-97.
14. 14 Lecouer HF, Truffor-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 1989; 140: 1189-93.
15. 15 Hong Kong Chest Service/British Medical Research Council Controlled trial of 2, 4 and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin and pyrazinamide: results at 30 months. Am Rev Respir Dis 1991; 143: 700-06.
16. 16 Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis A twice-weekly, directly observed, and cost-effecctive regimen. Ann Intern Med 1990; 112: 407-15.
17. 17 Desormeaux J, Johnson MP, Coberly JS, et al. Widespread HIV counseling and testing linked to a community-based tuberculosis control program in a high risk population. Bull Pan Am Health Organ 1996; 30: 1-8.
18. 18 Johnson MP, Coberly J, Clermont HC, et al. Tuberculin skin test reactivity among adults infected with human immunodeficiency virus. J Infect Dis 1992; 166: 194-98.
19. 19 Chaisson RE, Clermont HC, Holt EA, et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996; 154: 1034-38.
20. 20 Kent PT, Kubica GD. Public Health Mycobacteriology: a guide for the Level III Laboratory. Centers for Disease Control, Atlanta. 1985.
21. 21 Small PM, Shafer RW, Hopewell PC, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993; 328: 1137-41.
22. 22 Ji B, Truffot-Pernot C, Lacroix C, et al. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis 1993; 148: 1541-46.
23. 23 Eldred LJ, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J AIDS 1997 (in press).
24. 24 Bloch AB, Cauthen GM, Onorato IM, et al. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA 1994; 271: 665-71.
25. 25 Chaulet P, Boulahbal F, Grosset J. Surveillance of drug-resistance for tuberculosis control: why and how. Tuber Lung Dis 1995; 76: 487-92.
26. 26 Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Uganda adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997; 337: 801-08.
27. 27 Wallis RS, Vjecha M, Amir-Tahmasseb M, et al. Influence of tuberculosis on human immunodeficiency virus (HIV-1): enhanced cytokine expression and elevated beta-2 microglobulin in HIV-1 associated tuberculosis. J Infect Dis 1993; 167: 43-48.
28. 28 Greenberg AE, Lucas S, Tossuo O, et al. Autopsy-proven causes of death in HIV-infected patients treated for tuberculosis in Abidjan, Cote D'Ivoire. AIDS 1995; 9: 1251-54.
29. 29 Raviglione MC, Narain JP, Kocki A. HIV-associated tuberculosis in developing countries: clinical features, diagnosis and treatment. Bull World Health Organ 1992; 70: 515-26.
30. 30 Blower SM, Small PM, Hopewell PC. Control strategies for tuberculosis epidemics: new models for old problems. Science 1996; 273: 497-500.
31. 31 Murray CJL, Styblo K, Rouillon A. Tuberculosis in developing countries: burden, intervention and cost. Bull Int Union Tuberc Lung Dis 1990; 65: 6-24.